Results 201 to 210 of about 70,337 (231)
Some of the next articles are maybe not open access.
Triple-negative Breast Cancer and Poly(ADP-ribose) Polymerase Inhibitors
Anti-Cancer Agents in Medicinal Chemistry, 2012Recent gene profiling studies have identified at least 5 major subtypes of breast cancer, including normal type, luminal A type, luminal B type, human epidermal growth factor receptor (HER)-2 positive type, and basal-like type. Triple-negative breast cancer (TNBC), showing no or low expressions of estrogen receptor (ER), progesterone receptor (PgR ...
Youngjin, Park +5 more
openaire +2 more sources
Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors
Pharmacological Research, 2002Poly(ADP-ribose) polymerases (PARPs) are defined as cell signaling enzymes that catalyze the transfer of ADP-ribose units from NAD(+)to a number of acceptor proteins. PARP-1, the best characterized member of the PARP family, that presently includes six members, is an abundant nuclear enzyme implicated in cellular responses to DNA injury provoked by ...
TENTORI, LUCIO +2 more
openaire +3 more sources
Relevance of poly (ADP-ribose) polymerase inhibitors in prostate cancer
Current Opinion in Supportive & Palliative Care, 2018Purpose of review Poly (ADP-ribose) polymerase inhibitors (PARPi) are approved drugs for the treatment of ovarian and breast cancer and currently under investigation for the treatment of prostate cancer and other malignancies with aberrations in homologous recombination DNA repair.
Pasquale, Rescigno +2 more
openaire +2 more sources
Poly(ADP-ribose) polymerase (PARP) and PARP inhibitors
Drug Discovery Today: Disease Models, 2012PARP-1 protects cells from endogenous and therapeutically inflicted DNA damage. PARP inhibitors have been under development since 1980 and first entered clinical trial in 2003. They are an exciting new class of drugs that have the potential to increase the efficacy of anticancer DNA damaging agents and to selectively target cells that have defects in ...
openaire +2 more sources
The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities
Gynecologic Oncology, 2018Niraparib is an oral poly(ADP ribose) polymerase (PARP) inhibitor that is currently approved by the United States Food and Drug Administration (US FDA) as well as recently approved by the European Medicines Agency (EMA) for the maintenance treatment of women with recurrent ovarian cancer who are in complete or partial response to platinum-based ...
Kathleen N, Moore +2 more
openaire +2 more sources
Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics
Anti-Cancer Agents in Medicinal Chemistry, 2019Background:Poly-ADP-ribosylation, that is, adding ADP-ribose moieties to a protein, is a unique type of protein post-translational modification that regulates various cellular processes such as DNA repair, mitosis, transcription, and cell growth. Small-molecule inhibitors of poly-ADP-ribose polymerase 1 (PARP1) have been developed as anticancer agents ...
Nan, Li +3 more
openaire +2 more sources
Poly(ADP-ribose)polymerase (PARP) Inhibitors: From Bench to Bedside
Clinical Oncology, 2014Poly(ADP-ribose)polymerase (PARP) inhibitors are a novel class of anticancer agents that target the DNA damage response pathways. The enzyme target, PARP, plays a key role in signalling DNA single-strand breaks. Clinical development to date has focused on their potential role in combination with DNA-damaging chemotherapy, where efficacy has been ...
openaire +3 more sources
Long-Acting Poly(ADP-ribose) Polymerase Inhibitor Prodrug for Humans
Bioconjugate ChemistryPoly(ADP-ribose) polymerase inhibitors (PARPi) have been approved for once or twice daily oral use in the treatment of cancers with BRCA defects. However, for some patients, oral administration of PARPi may be impractical or intolerable, and a long-acting injectable formulation is desirable.
Christopher W. Carreras +4 more
openaire +2 more sources
Targeting angiogenesis with poly(ADP-ribose) polymerase inhibitors
2007The process of angiogenesis is mediated by a wide range of factors, including pro-inflammatory cytokines. On the basis of the involvement of inflammation in tumor development and of the dual role of PARP inhibitor as enhancer of chemotherapy or as anti-inflammatory agent we have investigated the ability of PARP inhibitors to affect endothelial ...
MUZI, ALESSIA +9 more
openaire +1 more source
Roles of mRNA poly(A) tails in regulation of eukaryotic gene expression
Nature Reviews Molecular Cell Biology, 2021Lori Anne Passmore, Jeff Coller
exaly